RAP 0.00% 20.5¢ raptor resources limited

Ann: Broker Meets Biotech Presentation, page-2

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 729 Posts.
    lightbulb Created with Sketch. 405
    The key measures of a diagnostic tool include accuracy, cost per test and timeliness. The accuracy has to be high enough to make the test helpful, however, a very low cost and a fast examination time can compensate the flaw of false negative result. For example, if a single test will give a 20% false negative probability, then doing two tests will give just 4% (i.e. neither of the tests reports a positive result). Therefore, in theory, multiple tests to increase confidence of disease detection is feasible if the cost is low enough. So I believe AI in diagnostic medicine is the future and thanks to the people pushing the field so fast!
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.